Key result
Atorvastatin ameliorated lipid overload-induced mitochondrial dysfunction and cardiac hypertrophy by decreasing myocardial fatty acid oxidation via inactivation of the p-STAT3/CPT1 pathway.
Why the study?
Statins exhibit cholesterol-independent cardiac pleiotropic effects, but the underlying mechanisms and potential association with fatty acid oxidation regulation remain unclear.
Atorvastatin exerts cholesterol-independent cardioprotective effects against lipid overload-induced hypertrophy by modulating fatty acid oxidation via the p-STAT3/CPT1 pathway.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for atorvastatin in lipid overload cardiomyopathy; prospective trials needed before clinical adoption.
Although statins are shown to have cardiac pleiotropic effects independent of lowering cholesterol, the underlying mechanism remains unclear. Mitochondrial dysfunction induced by increased fatty acid oxidation (FAO) is the culprit in the development of cardiac hypertrophy and dysfunction. This study was to explore whether the cardiac pleiotropic effects of atorvastatin were associated with FAO regulation, with a specific focus on carnitine palmitoyltransferase 1 (CPT1). High-fat diet (HFD)-fed mice and palmitic acid (PA)-stimulated neonatal rat primary cardiomyocytes (NRCMs) were treated with atorvastatin, with or without FAO modulators, signal transducer and activator of transcription 3 (STAT3) agonist, and inhibitor. Atorvastatin (3 mg/kg) did not reduce serum cholesterol levels in HFD-fed mice but ameliorated mitochondrial dysfunction and cardiac hypertrophy. In vitro, atorvastatin and the FAO inhibitor alleviated PA-induced mitochondrial dysfunction and cardiomyocyte hypertrophy. However, the FAO enhancer eliminated atorvastatin's protective effects. Furthermore, atorvastatin decreased CPT1 and FAO levels and prevented STAT3 phosphorylation and nuclear translocation. STAT3 inhibitor had the same inhibitory effects as atorvastatin on CPT1, FAO levels, and cardiomyocyte hypertrophy, whereas STAT3 agonist disrupted these effects of atorvastatin. Our results demonstrate that atorvastatin decreases myocardial FAO by inactivating the p-STAT3/CPT1 signaling pathway, which improves lipid overload-induced mitochondrial dysfunction and cardiac hypertrophy in a cholesterol-independent manner. This is the first study to explore the cardiac pleiotropic effects of atorvastatin with respect to FAO. However, whether atorvastatin regulates FAO in the cardiac hypertrophy model induced by other variables has not been investigated in this work, and this is expected to be performed in the future.
No takes yet. Share an insight, caveat, or question.
Zheng et al. (2022) studied Lipid overload-induced mitochondrial dysfunction and myocardial hypertrophy. Atorvastatin vs. Control (no atorvastatin) was evaluated on Mitochondrial dysfunction and cardiac hypertrophy. Atorvastatin ameliorated lipid overload-induced mitochondrial dysfunction and cardiac hypertrophy by decreasing myocardial fatty acid oxidation via inactivation of the p-STAT3/CPT1 pathway.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: